Roxadimate
CAS 58882-17-0
Roxadimate (CAS 58882-17-0) is a Phase 2 pharmaceutical compound with 0 bioactivity targets and 0 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Roxadimate used for in pharmaceutical contexts?
Roxadimate (CAS 58882-17-0) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Roxadimate?
No adverse-event association or SIDER side-effect rows are rendered for Roxadimate in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Roxadimate also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Ethyl Dihydroxypropyl Aminobenzoate with EU status "restricted".
What clinical phase is Roxadimate in?
Roxadimate is rendered with ChEMBL max phase 2.